Aerovate Therapeutics, Inc. – AVTE
Aerovate Therapeutics, Inc. (Nasdaq: AVTE), relating to a proposed merger with Jade Biosciences. Under the terms of the agreement, pre-merger Aerovate stockholders are expected to own approximately 1.6% of the combined company, while pre-merger Jade stockholders are expected to own approximately 98.4% of the combined entity.